Romiplostim management of immune thrombocytopenic purpura

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 914-919

  Ipema, Heather J ^a   Jung, Michelle Y ^a   Lodolce, Amy E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura; Romiplostim

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; DANAZOL; ROMIPLOSTIM;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BLEEDING; CELL LEVEL; CIRCULATION; CLINICAL TRIAL; CONTUSION; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIUM CELL; EPISTAXIS; FATIGUE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MEGAKARYOPOIESIS; MYALGIA; MYELODYSPLASTIC SYNDROME; PAIN; PARESTHESIA; PRIORITY JOURNAL; SHOULDER PAIN; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT RESPONSE;

CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC;

EID: 65749112759     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L643     Document Type: Article

References (17)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008. DOI 10.1056/NEJMra010501
2. Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 2007;14:511-514 DOI 10.1097/MOH.0b013e3282ba5552 (Pubitemid 47457642)
3. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
4. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596
5. Godeau B, Provan D, Bussell J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007;14:535-556 (Pubitemid 47457646)
6. U.S. Food and Drug Administration. Drugs @ FDA: FDA approved drug products. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails&#totable (accessed 2008 Dec 4).
7. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628-638 DOI 10.1016/j.clpt.2004.08.010 (Pubitemid 39601552)
8. Product information. NPlate (romiplostim). Thousand Oaks, CA: Amgen Inc., August 2008.
9. Newland A. Emerging strategies to treat chronic immune thrombocytopenic purpura. Eur J Haematol 2008;80:27-33.
10. Nichol JL. AMG 531: an investigational thrombopoiesis-stimulating peptibody. Pediatr Blood Cancer 2006;47(5 suppl):723-725 DOI 10.1002/pbc.20972
11. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13. DOI 10.1160/TH07-08-0513
12. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16. DOI 10.1182/blood-2006-10-019315
13. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371:395-403. DOI 10.1016/S0140-6736(08)60203-60212
14. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-71. DOI 10.1182/blood-2008-04-150078
15. Kantarjian HM, Giles FJ, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): preliminary results of a phase 1/2 study (abstract 7032). J Clin Oncol 2008;25. http://meeting.ascopubs. org/cgi/content/abstract/25/18-suppl/ 7032 (accessed 2009 Apr 10).
16. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in patients with low-risk myelodysplastic syndrome and thrombocytopenia: update including extended treatment. Presented at: 2007 Annual Meeting of the American Society of Hematology, December 8-11, 2007, Atlanta, GA.
17. Engel K, ed. 2008 Red book and updates. Montvale, NJ: Thomson Healthcare, 2008.